Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Chemours CoCC · Entity 4420 | Director | April 26, 2023 | April 28, 2023 |
| ON SEMICONDUCTOR CORPON · Entity 3161 | Director | June 03, 2019 | June 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Chemours Co
Report date April 26, 2023 · Filed April 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common STockSEC Table I · non-derivative | Direct | 107,148.3173 |
Reported balance
After 2023-04-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-04-26 · Grant · Acquired 5,858 · Balance 107,148.3173 F1: Includes directly owned shares, stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 47 |
Reported balance
Holding disclosure · report date 2023-04-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 47 |
| Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,395.4764 |
Reported balance
Holding disclosure · report date 2023-04-26 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 16,395.4764 F2: Units are credited under the Chemours deferred compensation plan for directors and convert one-for-one to Chemours common stock. F3: Payable upon separation from service. F4: Includes stock units and dividend equivalent units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes directly owned shares, stock units and dividend equivalent units.
F2: Units are credited under the Chemours deferred compensation plan for directors and convert one-for-one to Chemours common stock.
F3: Payable upon separation from service.
F4: Includes stock units and dividend equivalent units.
ON SEMICONDUCTOR CORP
Report date June 03, 2019 · Filed June 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 239,380 |
Reported balance
After 2019-06-03 transaction · row 1
1 source rowRow 1 · 2019-06-03 · Grant · Acquired 11,339 · Balance 239,380 F1: On May 8, 2019, the Compensation Committee of the Board of Directors of the Issuer approved the award of fully-vested stock to the Reporting Person under the Issuer's Amended and Restated Stock Incentive Plan (the "Plan") with a grant date of June 3, 2019, subject to the terms and conditions of the Plan and the relevant award agreement. This award was for no consideration other than service as a member of the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 8, 2019, the Compensation Committee of the Board of Directors of the Issuer approved the award of fully-vested stock to the Reporting Person under the Issuer's Amended and Restated Stock Incentive Plan (the "Plan") with a grant date of June 3, 2019, subject to the terms and conditions of the Plan and the relevant award agreement. This award was for no consideration other than service as a member of the Issuer's Board of Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Xylem Inc.
Report date May 12, 2020 · Filed May 13, 2020
Section 16 reporting ended · disclosed 2020-05-13. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2023 Filed Apr 28, 2023 13:27 UTC | Chemours Co CC · Entity 4420 | GrantCommon STock | 5,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025989 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,148.3173 F1 · balance_after: Includes directly owned shares, stock units and dividend equivalent units. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 10:11 UTC | Chemours Co CC · Entity 4420 | GrantCommon Stock | 4,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001627223-22-000028 · primary_doc.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,022.8654 F1 · balance_after: Includes directly owned shares, stock units and dividend equivalent units. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 17:12 UTC | Chemours Co CC · Entity 4420 | GrantCommon Stock | 4,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001627223-21-000030 · primary_doc.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,913.8798 F1 · balance_after: Includes directly owned shares, stock units and dividend equivalent units. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 21:01 UTC | Chemours Co CC · Entity 4420 | GrantCommon Stock | 12,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001627223-20-000031 · primary_doc.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,312 F1 · balance_after: Includes stock units and dividend equivalent units. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 13:42 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 7,500 | $78.69 | $590,154.75 |
DisclosureSEC source: 0001209191-19-055626 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,575 F1 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $ 78.67 to $78.74 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 18:18 UTC | ON SEMICONDUCTOR CORP ON · Entity 3161 | GrantCommon | 11,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008914 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,380 F1 · shares: On May 8, 2019, the Compensation Committee of the Board of Directors of the Issuer approved the award of fully-vested stock to the Reporting Person under the Issuer's Amended and Restated Stock Incentive Plan (the "Plan") with a grant date of June 3, 2019, subject to the terms and conditions of the Plan and the relevant award agreement. This award was for no consideration other than service as a member of the Issuer's Board of Directors. Read SEC document |
| May 15, 2019 Filed May 17, 2019 15:46 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 1,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030827 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,075 F1 · shares: Reflects the award of restricted stock units, which are scheduled to vest on the business day prior to the Xylem Inc. 2020 annual shareholders' meeting. Read SEC document |
| May 07, 2019 Filed May 8, 2019 14:15 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 7,500 | $79.20 | $593,980.50 |
DisclosureSEC source: 0001209191-19-028198 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,244 F1 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $79.1910 to $79.2091 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:52 UTC | Chemours Co CC · Entity 4420 | GrantCommon Stock | 4,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001627223-19-000027 · primary_doc.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,979 F1 · balance_after: Includes stock units and dividend equivalent units. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 15:47 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 7,500 | $76.60 | $574,500.75 |
DisclosureSEC source: 0001209191-19-019962 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,744 F1 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $76.59 to $76.62 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| August 07, 2018 Filed Aug 7, 2018 14:51 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 6,177 | $76.48 | $472,416.96 |
DisclosureSEC source: 0001209191-18-045649 · doc4.xml · nonDerivative · entry 2 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,244 F2 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $76.37 to $76.53 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 14:51 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 1,323 | $75.25 | $99,555.75 |
DisclosureSEC source: 0001209191-18-045649 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,421 F1 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $75.24 to $75.3 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 18:18 UTC | ON SEMICONDUCTOR CORP ON · Entity 3161 | GrantCommon | 7,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-010284 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,041 F1 · shares: On May 16, 2018, the Compensation Committee of the Board of Directors of the Issuer approved the award of fully-vested stock to the Reporting Person under the Issuer's Amended and Restated Stock Incentive Plan (the "Plan") with a grant date of June 4, 2018, subject to the terms and conditions of the Plan and the relevant award agreement. This award was for no consideration other than service as a member of the Issuer's Board of Directors. Read SEC document |
| May 14, 2018 Filed May 15, 2018 09:41 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 7,500 | $73.39 | $550,395.00 |
DisclosureSEC source: 0001209191-18-030102 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,744 F1 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $73.32 to $73.46 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| May 09, 2018 Filed May 10, 2018 13:04 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 1,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-029124 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,244 F1 · shares: Reflects the award of restricted stock units, which are scheduled to vest on the business day prior to the Xylem Inc. 2019 annual shareholders' meeting. Read SEC document |
| May 02, 2018 Filed May 4, 2018 21:50 UTC | Chemours Co CC · Entity 4420 | GrantCommon Stock | 2,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001627223-18-000029 · primary_doc.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,282 F1 · balance_after: Includes stock units and dividend equivalent units. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 14:35 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,860 | $0.00 Strike: $30.02 | $0.00 |
DisclosureSEC source: 0001209191-18-009106 · doc4.xml · derivative · entry 4 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common stock · 2,860 shares Expires 2020-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 14:35 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 5,088 | $71.72 | $364,911.36 |
DisclosureSEC source: 0001209191-18-009106 · doc4.xml · nonDerivative · entry 3 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,297 F2 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $71.72 to $71.73 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 14:35 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 2,860 | $71.85 | $205,491.00 |
DisclosureSEC source: 0001209191-18-009106 · doc4.xml · nonDerivative · entry 2 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,385 F1 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $71.85 to $71.86 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 14:35 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionCommon Stock | 2,860 | $30.02 | $85,857.20 |
DisclosureSEC source: 0001209191-18-009106 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 09:58 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 7,500 | $66.44 | $498,307.50 |
DisclosureSEC source: 0001209191-17-060153 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,385 F1 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $66.36 to $66.50 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 18:38 UTC | ON SEMICONDUCTOR CORP ON · Entity 3161 | GrantCommon | 12,726 | $16.11 | $205,015.86 |
DisclosureSEC source: 0001225208-17-010996 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,216 F1 · shares: On May 17, 2017, the Compensation Committee of the Board of Directors of the Issuer approved the award of fully-vested stock to the Reporting Person under the Issuer's Amended and Restated Stock Incentive Plan (the "Plan"), with a grant date of June 5, 2017, subject to the terms and conditions of the Plan and the relevant award agreement. This award was for no consideration other than service as a member of the Issuer's Board of Directors. Read SEC document |
| May 10, 2017 Filed May 11, 2017 19:35 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 2,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031659 · doc4.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,885 F1 · shares: Reflects the award of restricted stock units, which are scheduled to vest on the business day prior to the Xylem Inc. 2018 annual shareholders' meeting. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 21:25 UTC | Chemours Co CC · Entity 4420 | GrantCommon Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001627223-17-000035 · primary_doc.xml · nonDerivative · entry 1 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,285 F1 · shares: Restricted stock units (RSUs) that vest upon separation from service. F2 · balance_after: Includes unvested RSUs and dividend equivalent units. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 20:39 UTC | Chemours Co CC · Entity 4420 | GrantStock Units · Derivative | 589 | $21.22 | $12,498.58 |
DisclosureSEC source: 0001627223-17-000002 · primary_doc.xml · derivative · entry 3 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,260 Underlying: Common Stock · 589 shares Expires not disclosed F2 · derivative.exercise_price: Units are credited under the Chemours deferred compensation plan for directors and convert one-for-one to Chemours common stock. F2 · shares: Units are credited under the Chemours deferred compensation plan for directors and convert one-for-one to Chemours common stock. F3 · derivative.exercise_date: Payable upon separation from service. F3 · derivative.expiration_date: Payable upon separation from service. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:42 UTC | Chemours Co CC · Entity 4420 | GrantStock Units · Derivative | 781.25 | $16.00 | $12,500.00 |
DisclosureSEC source: 0001627223-16-000142 · primary_doc.xml · derivative · entry 3 CRAWFORD CURTIS J · CIK 0001014318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,670.8 Underlying: Common Stock · 781.25 shares Expires not disclosed F2 · derivative.exercise_price: Units are credited under the Chemours deferred compensation plan for directors and convert one-for-one to Chemours common stock. F2 · shares: Units are credited under the Chemours deferred compensation plan for directors and convert one-for-one to Chemours common stock. F3 · derivative.exercise_date: Payable upon separation from service. F3 · derivative.expiration_date: Payable upon separation from service. F4 · balance_after: Includes stock units and dividend equivalent units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.